person · Reporting owner

Terifay Robert J

Disclosed activity across 1 company

Tapewire entity: 171198
SEC CIK: 0001391382

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010	EVP Commercial	December 12, 2017	December 13, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

REGENERON PHARMACEUTICALS, INC.

Report date December 12, 2017 · Filed December 13, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $378.98 · Expires 2027-12-12	Direct	32,300	Reported balance After 2017-12-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-12-12 · Grant · Acquired 32,300 · Balance 32,300 F1: The stock option award vests in four equal annual installments, commencing one year after the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option award vests in four equal annual installments, commencing one year after the date of grant.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 12, 2017 Filed Dec 13, 2017 21:52 UTC	REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010	GrantNon-Qualified Stock Option (right to buy) · Derivative	32,300	$0.00 Strike: $378.98	$0.00	Disclosure SEC source: 0001237899-17-000026 · edgardoc.xml · derivative · entry 1 Terifay Robert J · CIK 0001391382 · EVP Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,300 Underlying: Common Stock · 32,300 shares Expires 2027-12-12 F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document
August 10, 2017 Filed Aug 11, 2017 20:02 UTC	REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010	Exercise / conversionIncentive Stock Option (right to buy) · Derivative	1,921	$0.00 Strike: $52.03	$0.00	Disclosure SEC source: 0001708138-17-000013 · edgardoc.xml · derivative · entry 3 Terifay Robert J · CIK 0001391382 · EVP Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,921 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document
August 10, 2017 Filed Aug 11, 2017 20:02 UTC	REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010	Exercise / conversionCommon Stock	1,921	$52.03	$99,949.63	Disclosure SEC source: 0001708138-17-000013 · edgardoc.xml · nonDerivative · entry 1 Terifay Robert J · CIK 0001391382 · EVP Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 16, 2017 Filed Jun 19, 2017 20:44 UTC	REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010	SaleCommon Stock	21,147	$468.19	$9,900,813.93	Disclosure SEC source: 0001708138-17-000007 · edgardoc.xml · nonDerivative · entry 4 Terifay Robert J · CIK 0001391382 · EVP Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,293 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document
June 15, 2017 Filed Jun 19, 2017 20:44 UTC	REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	48,750	$0.00 Strike: $52.03	$0.00	Disclosure SEC source: 0001708138-17-000007 · edgardoc.xml · derivative · entry 6 Terifay Robert J · CIK 0001391382 · EVP Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,579 Underlying: Common Stock · 48,750 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: The option became exercisable with respect to all shares underlying the option on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. Read SEC document
June 15, 2017 Filed Jun 19, 2017 20:44 UTC	REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010	Tax withholdingCommon Stock	22,192	$468.69	$10,401,168.48	Disclosure SEC source: 0001708138-17-000007 · edgardoc.xml · nonDerivative · entry 3 Terifay Robert J · CIK 0001391382 · EVP Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,440 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document
June 15, 2017 Filed Jun 19, 2017 20:44 UTC	REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010	Tax withholdingCommon Stock	5,411	$468.69	$2,536,081.59	Disclosure SEC source: 0001708138-17-000007 · edgardoc.xml · nonDerivative · entry 2 Terifay Robert J · CIK 0001391382 · EVP Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,632 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document
June 15, 2017 Filed Jun 19, 2017 20:44 UTC	REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010	Exercise / conversionCommon Stock	48,750	$52.03	$2,536,462.50	Disclosure SEC source: 0001708138-17-000007 · edgardoc.xml · nonDerivative · entry 1 Terifay Robert J · CIK 0001391382 · EVP Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,043 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document
December 16, 2016 Filed Dec 19, 2016 21:16 UTC	REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010	GrantNon-Qualified Stock Option (right to buy) · Derivative	34,000	$0.00 Strike: $381.92	$0.00	Disclosure SEC source: 0001237899-16-000090 · edgardoc.xml · derivative · entry 1 Terifay Robert J · CIK 0001391382 · EVP Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2026-12-16 F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.